RecruitingNCT07423429
Study of Switching to Aflibercept 8 mg in Patients With Refractory or Dependent Exudative Age-related Macular Degeneration
Phase not reported · 100 planned enrolment
- Countries listed
- 1
- Registry update
- June 25, 2026
Registry Intervention View
aflibercept 8 mg
Trial registrations containing the exact intervention label aflibercept 8 mg.
Exact registry label · Not reported
3 linked registrations
No aliases or equivalent products have been inferred.
Topics connected by trial metadata
0 linked registrations report posted results
This is a registry availability fact, not a safety result, comparison, or conclusion.
Understand the safety boundary →Registered trials
Not Yet RecruitingNCT07489586
A Clinical Study of QL1207H Injection Versus Aflibercept for Neovascular Age-related Macular Degeneration
PHASE3 · 356 planned enrolment
- Countries listed
- 0
- Registry update
- March 24, 2026
WithdrawnNCT06398080
An Observational Study to Investigate the Use of Aflibercept 8 mg to Treat Adult Patients With Neovascular Age-Related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME) in a Real-World Setting
Phase not reported · 0 planned enrolment
- Countries listed
- 0
- Registry update
- November 25, 2024